The blockade of immune checkpoints in cancer immunotherapy
Explore this paper's citation graph
Summary
Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
- Type
- review
- Published
- 2012-03-22
- Cited by
- 12,963
- References
- 135
- Access
- Open access
- OpenAlex
- https://openalex.org/W2066671159
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:19190366
Keywords
Immune system, Immunotherapy, Immune checkpoint, Immunology, Antigen
References
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
- LAG-3 in Cancer Immunotherapy
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
- Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses1
- Cutting Edge: CTLA-4 (CD152) Differentially Regulates Mitogen-Activated Protein Kinases (Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase) in CD4+ T Cells from Receptor/Ligand-Deficient Mice1
- Foxp3-dependent programme of regulatory T-cell differentiation
- Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
- Up on the tightrope: natural killer cell activation and inhibition
- Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.
- IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells.
- Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
- A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.
- Dual biological effects of the cytokines interleukin-10 and interferon-γ
- CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- Role of LAG-3 in regulatory T cells.
- T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.
- LAG-3, a novel lymphocyte activation gene closely related to CD4
Cited by
- The targeting of immunosuppressive mechanisms in hematological malignancies
- PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
- Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
- PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
- Immune-mediated antitumor effect by type 2 diabetes drug, metformin
- Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
- Differential fates of biomolecules delivered to target cells via extracellular vesicles
- Pathogenesis beyond the cancer clone(s) in multiple myeloma.
- CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back
- Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
- Toward Localized In Vivo Biomarker Concentration Measurements
- Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma
- CTLA-4 and PD-1 Pathways
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
- In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
- PD-L1-specific T cells
- Functional Immune Anatomy of the Liver—As an Allograft
- Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Related papers
- The Role of Pd-L1 on Tumor Cells in Host Immune System Escape and Tumor Immunotherapy by Pd-L1 Blockade; Immune Checkpoint Blockade in Cancer Immunotherapy
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
- Metastatic Melanoma and immunotherapy
- PD‐1/PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
- Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy
- Tumor Associated Immune Dysfunction: Immune Cells Involved and Suggested Therapies
- Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
- Regulatory T cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors
- Immunotherapy and predictive immunologic profile: the tip of the iceberg